Yamashita Shingo, Ohashi Kazuo, Utoh Rie, Kin Tatsuya, Shapiro A M James, Yamamoto Masakazu, Gotoh Mitsukazu, Okano Teruo
Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University , Tokyo , Japan.
Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan; †Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
Cell Med. 2013 Oct 23;6(1-2):33-8. doi: 10.3727/215517913X674243. eCollection 2013 Dec 30.
In new generation medical therapies for type 1 diabetes mellitus (DM), cell-based approaches using pancreatic islets have attracted significant attention worldwide. In particular, dispersed islet cells obtained from isolated pancreatic islets have been a valuable source in the cell biology and tissue engineering fields. Our experimental approach to the development of new islet-based DM therapies consisted of creating a monolithic islet cell sheet format using dispersed islet cells. In this experiment, we explored the potential of internationally transporting human islets from Alberta, Canada to Tokyo, Japan and obtaining viable dispersed islet cells. A total of 34 batches of isolated and purified human islets were transported using a commercial air courier service. Prior to shipping, the human islets had been in culture for 0-108 h at the University of Alberta. The transportation period from Alberta to Tokyo was 2-5 days. The transported human islet cells were enzymatically dispersed as single cells in Tokyo. The number of single islet cells decreased as the number of transportation days increased. In contrast, cell viability was maintained regardless of the number of transportation days. The preshipment culture time had no effect on the number or viability of single cells dispersed in Tokyo. When dispersed single islet cells were plated on laminin-5-coated temperature-responsive polymer-grafted culture dishes, the cells showed favorable attachment followed by extension as a monolithic format. The present study demonstrated that long-distance transported human islets are a viable cell source for experiments utilizing dispersed human islet cells.
在1型糖尿病(DM)的新一代医学疗法中,使用胰岛的细胞疗法已在全球引起了广泛关注。特别是,从分离的胰岛中获得的分散胰岛细胞一直是细胞生物学和组织工程领域的宝贵资源。我们开发基于胰岛的糖尿病新疗法的实验方法包括使用分散的胰岛细胞创建整体胰岛细胞片形式。在本实验中,我们探索了将人类胰岛从加拿大艾伯塔省国际运输到日本东京并获得存活的分散胰岛细胞的潜力。总共34批分离和纯化的人类胰岛通过商业航空快递服务进行运输。在运输之前,人类胰岛已在艾伯塔大学培养了0 - 108小时。从艾伯塔省到东京的运输时间为2 - 5天。运输的人类胰岛细胞在东京被酶解为单细胞。随着运输天数的增加,单个胰岛细胞的数量减少。相比之下,无论运输天数如何,细胞活力都得以维持。运输前的培养时间对在东京分散的单细胞数量或活力没有影响。当将分散的单个胰岛细胞接种在层粘连蛋白-5包被的温度响应性聚合物接枝培养皿上时,细胞表现出良好的附着,随后以整体形式伸展。本研究表明,长途运输的人类胰岛是利用分散的人类胰岛细胞进行实验的可行细胞来源。